Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 5/2011

01-10-2011 | Review

Bench-to-beside review: Acute-on-chronic liver failure - linking the gut, liver and systemic circulation

Authors: Len Verbeke, Frederik Nevens, Wim Laleman

Published in: Critical Care | Issue 5/2011

Login to get access

Abstract

The concept of acute-on-chronic liver failure (ACLF) was introduced recently to describe a subset of patients with chronic liver disease presenting with profound deterioration of liver function and rapidly evolving multi-organ failure. ACLF is frequently accompanied by the development of severe inflammatory response syndrome and has a high mortality. To date, treatment options are limited and exclusively supportive. Over the last few years, some insights have been generated in the pathophysiology of ACLF. A key role for the interaction of innate immune dysfunction, enhanced bacterial translocation from the gut, and circulatory dysfunction has been proposed. In this respect, therapeutic strategies have been examined, with variable success, in experimental studies in animals and humans. This review focuses on potentially relevant pathophysiological elements in the development of ACLF and points out promising treatment modalities in ACLF.
Appendix
Available only for authorised users
Literature
1.
Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H: Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs. 1993, 17: 809-813.CrossRefPubMed
2.
Jalan R, Williams R: Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 2002, 20: 252-261. 10.1159/000047017.CrossRefPubMed
3.
Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F: Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut. 2010, 59: 1561-1569. 10.1136/gut.2009.189639.CrossRefPubMed
4.
Hassanein TI, Tofteng F, Brown RS, McGuire B, Lynch P, Mehta R, Larsen FS, Gornbein J, Stange J, Blei AT: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007, 46: 1853-1862. 10.1002/hep.21930.CrossRefPubMed
5.
Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, Janssen HL, HBV 99-01 Study Group: Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut. 2005, 54: 1604-1609. 10.1136/gut.2004.062208.PubMedCentralCrossRefPubMed
6.
Lee KH, Lee MK, Sutedja DS, Lim SG: Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int. 2005, 25: 973-977. 10.1111/j.1478-3231.2005.01091.x.CrossRefPubMed
7.
Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, Siddiqui A, Jafri W: Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology. 2002, 36: 474-478.CrossRefPubMed
8.
Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009, 3: 269-282. 10.1007/s12072-008-9106-x.PubMedCentralCrossRefPubMed
9.
Sen S, Williams R, Jalan R: The pathophysiological basis of acute-on-chronic liver failure. Liver. 2002, 22: 5-13. 10.1034/j.1600-0676.2002.00001.x.CrossRefPubMed
10.
Leber B, Mayrhauser U, Rybczynski M, Stadlbauer V: Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochenschr. 2009, 121: 732-744. 10.1007/s00508-009-1288-2.CrossRefPubMed
11.
Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F: The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol. 2009, 51: 475-482. 10.1016/j.jhep.2009.04.017.CrossRefPubMed
12.
Bilzer M, Roggel F, Gerbes AL: Role of Kupffer cells in host defense and liver disease. Liver Int. 2006, 26: 1175-1186. 10.1111/j.1478-3231.2006.01342.x.CrossRefPubMed
13.
Kolios G, Valatas V, Kouroumalis E: Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006, 12: 7413-7420.PubMedCentralPubMed
14.
Heymann F, Trautwein C, Tacke F: Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets. 2009, 8: 307-318. 10.2174/187152809789352230.CrossRefPubMed
15.
Prins HA, Meijer C, Boelens PG, Diks J, Holtz R, Masson S, Daveau M, Meijer S, Scotté M, van Leeuwen PA: Kupffer cell-depleted rats have a diminished acute-phase response following major liver resection. Shock. 2004, 21: 561-565. 10.1097/01.shk.0000126649.96850.36.CrossRefPubMed
16.
Sakamoto S, Okanoue T, Itoh Y, Nakagawa Y, Nakamura H, Morita A, Daimon Y, Sakamoto K, Yoshida N, Yoshikawa T, Kashima K: Involvement of Kupffer cells in the interaction between neutrophils and sinusoidal endothelial cells in rats. Shock. 2002, 18: 152-157. 10.1097/00024382-200208000-00011.CrossRefPubMed
17.
Jaeschke H, Farhood A: Kupffer cell activation after no-flow ischemia versus hemorrhagic shock. Free Radic Biol Med. 2002, 33: 210-219. 10.1016/S0891-5849(02)00867-5.CrossRefPubMed
18.
Pimentel-Nunes P, Roncon-Albuquerque R, Gonçalves N, Fernandes-Cerqueira C, Cardoso H, Bastos RP, Marques M, Marques C, Alexandre Sarmento J, Costa-Santos C, Macedo G, Pestana M, Dinis-Ribeiro M, Leite-Moreira AF: Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease. Liver Int. 2010, 30: 1003-1011. 10.1111/j.1478-3231.2010.02251.x.CrossRefPubMed
19.
Stadlbauer V, Shah N, de Oca Arjona MM, Mookerjee RP, Jalan R: Alcohol takes the toll on immune function. Liver Int. 2010, 30: 934-936. 10.1111/j.1478-3231.2010.02271.x.CrossRefPubMed
20.
Stadlbauer V, Mookerjee RP, Wright GA, Davies NA, Jürgens G, Hallström S, Jalan R: Role of Toll-like receptors 2,4 and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastroinstest Liver Physiol. 2009, 296 (1): G15-22.CrossRef
21.
Seki E, Brenner DA: Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008, 48: 322-335. 10.1002/hep.22306.CrossRefPubMed
22.
23.
Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D: Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol. 1999, 163: 1-5.PubMed
24.
Steib CJ, Bilzer M, Härtl JM, Beitinger F, Gülberg V, Göke B, Gerbes AL: Kupffer cell activation by hydrogen peroxide: a new mechanism of portal pressure increase. Shock. 2010, 33: 412-418. 10.1097/SHK.0b013e3181b85934.CrossRefPubMed
25.
Antoniades CG, Berry PA, Wendon JA, Vergani D: The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol. 2008, 49: 845-861. 10.1016/j.jhep.2008.08.009.CrossRefPubMed
26.
Vollmar B, Menger MD: The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev. 2009, 89: 1269-1339. 10.1152/physrev.00027.2008.CrossRefPubMed
27.
Steinhoff G, Behrend M, Schrader B, Duijvestijn AM, Wonigeit K: Expression patterns of leukocyte adhesion ligand molecules on human liver endothelia Lack of ELAM-1 and CD62 inducibility on sinusoidal endothelia and distinct distribution of VCAM-1, ICAM-1, ICAM-2 and LFA-3. Am J Pathol. 1993, 142: 481-488.PubMedCentralPubMed
28.
Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C, Housset C: Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology. 1998, 27: 472-480. 10.1002/hep.510270222.CrossRefPubMed
29.
Steib CJ, Hartmann AC, v Hesler C, Benesic A, Hennenberg M, Bilzer M, Gerbes AL: Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest. 2010, 90: 1024-1032. 10.1038/labinvest.2010.60.CrossRefPubMed
30.
Brubaker Jo, Montaner LJ: Role of interleukin-13 in innate and adaptive immunity. Cell Mol Biol. 2001, 47: 637-651.PubMed
31.
Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA: Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta. J Exp Med. 2001, 194: 809-821. 10.1084/jem.194.6.809.PubMedCentralCrossRefPubMed
32.
Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, Tseng SC, Lin WP, Chen WT, Sheen IS: Endotoxinemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol. 2007, 46: 816-826. 10.1016/j.jhep.2006.12.018.CrossRefPubMed
33.
Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, Bach J, Geier A, Purucker EA, Gressner AM, Matern S, Lammert F: Patients with acute on chronic liver failure display 'sepsis-like' immune paralysis. J Hepatol. 2005, 42: 195-201.CrossRefPubMed
34.
Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R: Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol. 2006, 45: 280-289. 10.1016/j.jhep.2006.02.013.CrossRefPubMed
35.
Taïeb J, Mathurin P, Elbim C, Cluzel P, Arce-Vicioso M, Bernard B, Opolon P, Gougerot-Pocidalo MA, Poynard T, Chollet-Martin S: Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol. 2000, 32: 579-586. 10.1016/S0168-8278(00)80219-6.CrossRefPubMed
36.
Stanley AJ, MacGregor IR, Dillon JF, Bouchier IA, Hayes PC: Neutrophil activation in chronic liver disease. Eur J Gastroenterol Hepatol. 1996, 8: 135-138. 10.1097/00042737-199602000-00008.CrossRefPubMed
37.
Neugebauer H, Hartmann P, Krenn S, Glück T, Schölmerich J, Straub R, Wiest R: Bacterial translocation increases phagocytic activity of polymorphonuclear leucocytes in portal hypertension: priming independent of liver cirrhosis. Liver Int. 2008, 28: 1149-1157. 10.1111/j.1478-3231.2008.01829.x.CrossRefPubMed
38.
Feliu E, Gougerot MA, Hakim J, Cramer E, Auclair C, Rueff B, Boivin P: Blood polymorphonuclear dysfunction in patients with alcoholic cirrhosis. Eur J Clin Invest. 1977, 7: 571-577. 10.1111/j.1365-2362.1977.tb01653.x.CrossRefPubMed
39.
Abrahám S, Szabó A, Kaszaki J, Varga R, Eder K, Duda E, Lázár G, Tiszlavicz L, Boros M, Lázár G: Kupffer cell blockade improves the endotoxin-induced microcirculatory inflammatory response in obstructive jaundice. Shock. 2008, 30: 69-74.PubMed
40.
Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG: Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology. 1994, 20: 453-460. 10.1002/hep.1840200227.CrossRefPubMed
41.
Michael SL, Pumford NR, Mayeux PR, Niesman MR, Hinson JA: Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology. 1999, 30: 186-195. 10.1002/hep.510300104.CrossRefPubMed
42.
Mandal P, Pritchard MT, Nagy LE: Anti-inflammatory pathways and alcoholic liver disease: Role of an adiponectin/interleukin-10/heme-oxygenase-1 pathway. World J Gastroenterol. 2010, 16: 1330-1336. 10.3748/wjg.v16.i11.1330.PubMedCentralCrossRefPubMed
43.
Szabo G, Mandrekar P, Girouard L, Catalano D: Regulation of human monocyte functions by acute ethanol treatment: decreased tumor necrosis factor-α, interleukin-1β and elevated interleukin-10, and transforming growth factor-β production. Alcohol Clin Exp Res. 1996, 20: 900-907. 10.1111/j.1530-0277.1996.tb05269.x.CrossRefPubMed
44.
Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L: Understanding and treating patients with alcoholic cirrhosis: an update. Alcohol Clin Exp Res. 2009, 33: 1136-1144. 10.1111/j.1530-0277.2009.00956.x.CrossRefPubMed
45.
Notas G, Kisseleva T, Brenner D: NK and NKT cells in liver injury and fibrosis. Clin Immunol. 2009, 130: 16-26. 10.1016/j.clim.2008.08.008.CrossRefPubMed
46.
Suh YG, Jeong WI: Hepatic stellate cells and innate immunity in alcoholic liver disease. World J Gastroenterol. 2011, 17: 2543-51. 10.3748/wjg.v17.i20.2543.PubMedCentralCrossRefPubMed
47.
Bellot P, García-Pagán JC, Francés R, Abraldes JG, Navasa M, Pérez-Mateo M, Such J, Bosch J: Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010, 52: 2044-2052. 10.1002/hep.23918.CrossRefPubMed
48.
Guarner C, González-Navajas JM, Sánchez E, Soriando G, Francés R, Chiva M, Zapater P, Benlloch S, Muñoz C, Pascual S, Balanzó J, Pérez-Mateo M, Such J: The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology. 2006, 44: 633-639.CrossRefPubMed
49.
Cárdenas A, Ginès P: Acute-on-chronic liver failure: the kidneys. Curr Opin Crit Care. 2011, 17: 184-189. 10.1097/MCC.0b013e328344b3da.CrossRefPubMed
50.
Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, Carbonell N, Renard P, Ramond MJ, Moreau R, Poynard T, Pentocir Group: Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology. 2010, 138: 1755-1762. 10.1053/j.gastro.2010.01.040.CrossRefPubMed
51.
Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000, 119: 1637-1648. 10.1053/gast.2000.20189.CrossRefPubMed
52.
Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R: Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003, 38: 419-425.CrossRefPubMed
53.
Kanzler H, Barrat FJ, Hessel EM, Coffman RL: Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007, 13: 552-559. 10.1038/nm1589.CrossRefPubMed
54.
Garcia-Tsao G: Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol. 2004, 18: 353-372. 10.1016/j.bpg.2003.10.005.CrossRefPubMed
55.
Wiest R, Garcia-Tsao G: Bacterial translocation in cirrhosis. Hepatology. 2005, 41: 422-433. 10.1002/hep.20632.CrossRefPubMed
56.
Garcia-Tsao G, Albillos A, Barden GE, West AB: Bacterial translocation in acute and chronic portal hypertension. Hepatology. 1993, 17: 1081-1085. 10.1002/hep.1840170622.CrossRefPubMed
57.
Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, Fuster J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola A, Rodés J: Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001, 34: 32-37.CrossRefPubMed
58.
Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB: Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology. 1995, 108: 1835-1841. 10.1016/0016-5085(95)90147-7.CrossRefPubMed
59.
Sorell WT, Quigley EM, Jin G, Johnson TJ, Rikkers LF: Bacterial translocation in the portal-hypertensive rat: studies in basal condition and on exposure to hemorrhagic shock. Gastroenterology. 1993, 104: 1722-1726.PubMed
60.
Such J, Francés R, Muñoz C, Zapater P, Casellas JA, Cifuentes A, Rodríguez-Valera F, Pascual S, Sola-Vera J, Carnicer F, Uceda F, Palazón JM, Pérez-Mateo M: Detection and identifi cation of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology. 2002, 36: 135-141.CrossRefPubMed
61.
Wang W, Smail N, Wang P, Chaudry IH: Increased gut permeability after hemorrhage is associated with upregulation of local and systemic IL-6. J Surg Res. 1998, 79: 39-46. 10.1006/jsre.1998.5385.CrossRefPubMed
62.
Steffen EK, Berg RD, Deitch EA: Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis. 1988, 157: 1032-1038. 10.1093/infdis/157.5.1032.CrossRefPubMed
63.
Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE: Small intestinal overgrowth and bacterial translocation in human cirrhosis is associated with systemic endotoxinemia. Am J Gastroenterol. 2002, 97: 2364-2370. 10.1111/j.1572-0241.2002.05791.x.CrossRefPubMed
64.
Chang CS, Chen GH, Lien HC, Yeh HZ: Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998, 28: 1187-1190. 10.1002/hep.510280504.CrossRefPubMed
65.
Teshima CW, Meddings JB: The measurement and clinical significance of intestinal permeability. Curr Gastroenterol Rep. 2008, 10: 443-449. 10.1007/s11894-008-0083-y.CrossRefPubMed
66.
Pascual S, Such J, Esteban A, Zapater P, Casellas JA, Aparicio JR, Girona E, Gutiérrez A, Carnices F, Palazón JM, Sola-Vera J, Pérez-Mateo M: Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology. 2003, 50: 1482-1486.PubMed
67.
Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA: Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology. 2002, 35: 622-629. 10.1053/jhep.2002.31656.CrossRefPubMed
68.
Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M, International Ascites Club: Sepsis in cirrhosis: report on the 7th meeting of the international ascites club. Gut. 2005, 54: 718-725. 10.1136/gut.2004.038679.PubMedCentralCrossRefPubMed
69.
Tazi KA, Moreau R, Hervé P, Dauvergne A, Cazals-Hatem D, Bert F, Poirel O, Rabiller A, Lebrec D: Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology. 2005, 129: 303-314. 10.1053/j.gastro.2005.04.016.CrossRefPubMed
70.
Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis DG: Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009, 29: 992-999. 10.1111/j.1365-2036.2009.03958.x.CrossRefPubMed
71.
Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, Del Vecchio Blanco C, Loguercio C: Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis. 2011, 43: 431-438. 10.1016/j.dld.2010.10.015.CrossRefPubMed
72.
Martin PY, Xu DL, Niederberger M, Weigert A, Tsai P, St John J, Gines P, Schrier RW: Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol. 1996, 270: F494-499.PubMed
73.
Fernández M, García-Pagán JC, Casadevall M, Bernadich C, Piera C, Whittle BJ, Piqué JM, Bosch J, Rodés J: Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats. Gastroenterology. 1995, 108: 1487-1495. 10.1016/0016-5085(95)90698-3.CrossRefPubMed
74.
Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV: Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol. 1996, 25: 370-378. 10.1016/S0168-8278(96)80124-3.CrossRefPubMed
75.
Tazi KA, Barrière E, Moreau R, Heller J, Sogni P, Pateron D, Poirel O, Lebrec D: Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology. 2002, 122: 1869-1877. 10.1053/gast.2002.33586.CrossRefPubMed
76.
Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ: Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999, 104: 1223-1233. 10.1172/JCI7458.PubMedCentralCrossRefPubMed
77.
Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F: Portal hypertension: from pathophysiology to clinical practice. Liver Int. 2005, 25: 1079-1090. 10.1111/j.1478-3231.2005.01163.x.CrossRefPubMed
78.
Pannen BH, Bauer M, Nöldge-Schomburg GF, Zhang JX, Robotham JL, Clemens MG, Geiger KK: Regulation of hepatic blood flow during resuscitation from hemorrhagic shock: role of NO and endothelins. Am J Physiol. 1997, 272: H2736-2745.PubMed
79.
Steib CJ, Bilzer M, op den Winkel M, Pfeiler S, Hartmann AC, Hennenberg M, Göke B, Gerbes AL: Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology. 2010, 51: 2086-2096. 10.1002/hep.23596.CrossRefPubMed
80.
Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F: Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology. 2007, 132: 709-719. 10.1053/j.gastro.2006.12.041.CrossRefPubMed
81.
Rockey DC: Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis. 2001, 21: 337-349. 10.1055/s-2001-17551.CrossRefPubMed
82.
Laleman W, Van Landeghem L, Severi T, Vander Elst I, Zeegers M, Bisschops R, Van Pelt J, Roskams T, Cassiman D, Fevery J, Nevens F: Both Ca2+-dependent and independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol. 2007, 292: G556-564.CrossRefPubMed
83.
Baveja R, Kresge N, Ashburn JH, Keller S, Yokoyama Y, Sonin N, Zhang JX, Huynh T, Clemens MG: Potentiated hepatic microcirculatory response to endothelin-1 during polymicrobial sepsis. Shock. 2002, 18: 415-422. 10.1097/00024382-200211000-00005.CrossRefPubMed
84.
Pannen BH, Bauer M, Zhang JX, Robotham JL, Clemens MG: Endotoxin pretreatment enhances portal venous contractile response to endothelin-1. Am J Physiol. 1996, 270: H7-H15.PubMed
85.
Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP: A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992, 326: 507-512. 10.1056/NEJM199202203260802.CrossRefPubMed
86.
Rafailidis S, Ballas K, Psarras K, Pavlidis T, Emoniotou E, Papamichali R, Kalodimos G, Marakis G, Sakadamis A, Koukoulis G: Effect of early bosentan administration on the development of esophageal varices in cirrhotic rats: experimental study in Wistar rats. J Gastroenterol. 2008, 43: 897-904. 10.1007/s00535-008-2243-0.CrossRefPubMed
87.
Sogni P, Moreau R, Gomola A, Gadano A, Cailmail S, Calmus Y, Clozel M, Lebrec D: Benificial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology. 1998, 28: 655-659. 10.1002/hep.510280308.CrossRefPubMed
88.
Reichen J, Gerbes AL, Steiner MJ, Sägesser H, Clozel M: The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol. 1998, 28: 1020-1030. 10.1016/S0168-8278(98)80352-8.CrossRefPubMed
89.
Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM: Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007, 30: 338-344. 10.1183/09031936.00138706.CrossRefPubMed
90.
Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J: Bosentan therapy for portopulmonary hypetension. Eur Respir J. 2005, 25: 502-508. 10.1183/09031936.05.00080804.CrossRefPubMed
91.
Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, Martin A, Guimont MC, Cazals-Hatem D, Lebrec D: Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats. Gut. 2004, 53: 1844-1849. 10.1136/gut.2003.036517.PubMedCentralCrossRefPubMed
92.
Van de Casteele M, Omasta A, Janssens S, Roskams T, Desmet V, Nevens F, Fevery J: In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthesised carbon tetrachloride cirrhotic rats. Gut. 2002, 51: 440-445. 10.1136/gut.51.3.440.PubMedCentralCrossRefPubMed
93.
Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E, Acuto G, Clerici C, Baldoni M, Del Soldato P, Morelli A: NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol. 2003, 39: 940-946. 10.1016/j.jhep.2003.09.018.CrossRef
94.
Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Spénard J, Bosch J: NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Am J Gastroenterol. 2010, 105: 1094-1101. 10.1038/ajg.2009.661.CrossRefPubMed
95.
Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, Garca-Pagán JC, Rodés J, Bosch J: Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004, 126: 749-755. 10.1053/j.gastro.2003.12.007.CrossRefPubMed
96.
Hackam DG, Mamdani M, Li P, Redelmeier DA: Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006, 367: 413-418. 10.1016/S0140-6736(06)68041-0.CrossRefPubMed
97.
Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J: The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care. 2010, 25: 656.e7-22. 10.1016/j.jcrc.2010.02.013.CrossRef
98.
Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, Knawy BA, Hajeer AH, Tamimi W, Cherfan A: Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ. 2010, 182: 1971-1977. 10.1503/cmaj.090707.PubMedCentralCrossRefPubMed
99.
Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, Fevery J, Nevens F: Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care. 2006, 10: R108-10.1186/cc4985.PubMedCentralCrossRefPubMed
100.
Laleman W, Wilmer A, Evenepoel P: Review article: non-biological liver support in liver failure. Aliment Pharmacol Ther. 2006, 23: 351-363. 10.1111/j.1365-2036.2006.02765.x.CrossRefPubMed
Metadata
Title
Bench-to-beside review: Acute-on-chronic liver failure - linking the gut, liver and systemic circulation
Authors
Len Verbeke
Frederik Nevens
Wim Laleman
Publication date
01-10-2011
Publisher
BioMed Central
Published in
Critical Care / Issue 5/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc10424

Other articles of this Issue 5/2011

Critical Care 5/2011 Go to the issue

Commentary

Coenzyme Q10 deficiency in septic shock patients

Commentary

Rapid sequence induction with rocuronium - a challenge to the gold standard

Research

Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis

Journal club critique

Neuromuscular blockers and ARDS: Thou shalt not breathe, move, or die!

Commentary

A dynamic view of mHLA-DR expression in management of severe septic patients

Letter

Perioperative hemodynamic therapy: quality improvement programs should help to resolve our uncertainty